Efficacy and Safety of Onychomycosis Treatments: An Evidence-Based Overview

David M Pariser Md

doi:10.12788/j.sder.2015.0148

Efficacy and Safety of Onychomycosis Treatments: An Evidence-Based Overview

Semin Cutan Med Surg. 2015 Jun;34(3 Suppl):S46-50. doi: 10.12788/j.sder.2015.0148.

Author

David M Pariser Md¹

Affiliation

¹ Professor of Dermatology, Eastern Virginia Medical School, Department of Dermatology, Pariser Dermatology, Norfolk, Virginia.

PMID: 26624988
DOI: 10.12788/j.sder.2015.0148

Abstract

Three systemic agents commonly are used for the treatment of onychomycosis. Until the introduction of ciclopirox in 1999, these were the only FDA-approved therapeutic options for managing these infections. With the recent approval of two new topical antifungal agents-efinaconazole in the azole class, and tavaborole, a unique boron-containing medication- clinicians and patients have an improved roster of medications for managing onychomycosis. Semin Cutan Med Surg 34(supp3):S46-S50 © 2015 published by Frontline Medical Communications.

Keywords: Ciclopirox; dermatophyte infections; efinaconazole; fluconazole; itraconazole; laser therapy; onychomycosis; tavaborole; terbinafine.

2015 published by Frontline Medical Communications.